Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ori-C101 in GPC3-positive advanced hepatocellular carcinoma after at least second-line systemic therapy
CTR20223113Phase 2Active
- Sponsor
- OriCell Therapeutics
- Start
- Dec 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ORI-C101 in hepatocellular carcinoma (HCC), sponsored by OriCell Therapeutics. Started Dec 2022; status: active.
02
Drugs
ORI-C101
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20223113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223113.